Stuart Raetzman Appointed as Interim CEO at TearClear (Healio)

Stuart Raetzman Appointed as Interim CEO at TearClear

UF startup and UF Innovate | Sid Martin Biotech resident client TearClear has appointed Stuart Raetzman as interim CEO and is preparing for a pivotal study on proprietary latanoprost for glaucoma treatment, according to a press release.

“TearClear thanks Robert Dempsey for his contributions and wishes him well. We are excited for the company’s next chapter as we scale our platform and advance our innovative ophthalmic pharmaceutical portfolio. At TearClear, our goal is to disrupt the way current topical medications are delivered to the ocular surface,” Raetzman, a TearClear board member, said in the release.

Read more about Stuart Raetzman Appointed as Interim CEO at TearClear.
X